Article
Fixed-dose combination (ramipril-felodipine ER) in the first line therapy of essential hypertension ("IndComb"-Study)
Fixkombination - Ramipril plus Felodipin ER - Indikation in der first-line Therapie der essentiellen Hypertonie ("Indkomb"-Studie)
Search Medline for
Authors
Published: | November 11, 2004 |
---|
Outline
Text
The therapy of hypertension is characterized by an initial use of monotherapies, which are combined in the later course if necessary. Despite the availability of a large number of effective drugs, less than a quarter of hypertensive patients are normotensive worldwide. This poor situation leads to the question of a therapy-paradigm change, which was first official published in a statement at the JNC VII (2003).
To prove the hypothesis that fixed-dose combinations are not only more effective on long term but also safe in the first-line use, we conducted a randomised prospective multicenter pilot study, in which the fixed-dose combination of ramipril and felodipine ER was compared with the ramipril and felodipine monotherapy, in 150 patients with hypertension grad II-III. To identify symptomatic and asymptomatic hypotensive episodes we combined the 24-h-ambulatory-blood pressure monitoring (ABPM) on the first day of drug intake with a careful registration of all adverse events.
The acute effects on BP are listed in table 1 [Tab. 1]. There were no differences between the groups with regard to the number and intensity of the adverse effects. After 4 weeks of treatment the fixed-dose combination ram + fel lowered the systolic and diastolic blood pressure (office BP, daily profile of self-BP-measurement and ABPM) significantly more than the monotherapies. Furthermore the fixed-dose combination showed a trend for better tolerability.
The results support the primary use of the fixed-dose combination ramipril and felodipine in the arterial hypertension to improve the antihypertensive efficacy and tolerability, which should be re-evaluated in a further large double-blind study.